Positive PanCO trial update on resected cohort
Filed with ASX · · 3 pages · English
the PanCO trial in 2017. Typically such inoperable patients have median survival of ~8.5 months • Following treatment, 10 patients (23.8%) underwent surgical resection (removal of tumour), while another 4 were technically eligible for surgery but were unable to undergo surgery due toco- morbidities and/or other considerations. • A sub-group analysis has now been completed on the 10 resected patien
In the deck
Story so far
Earlier from OncoSil Medical
- Receipt of $2.8m R&D Tax Incentive Refund
- Investor Update
- OncoSil receives Malaysian regulatory approval
- Preliminary Final Report - Appendix 4E Announcement
- HDE filing submitted in US for Bile Duct Cancer treatment
Later from OncoSil Medical
- OncoSil achieves first commercial sale
- OncoSil receives Swiss regulatory approval
- Termination of Mr Daniel Kenny as Chief Executive Officer
- OncoSil FY21 half yearly review
- Appointment of Chief Executive Officer
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical